🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Locally Advanced, Recurrent or Metastatic Malignancies

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors NCT06390774Phase 11 site📍 Jinan Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Tests: SSGJ-705 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914Phase 31 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel, Capecitabine Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) NCT07241793Phase 26 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Sun Yat-sen University · Tests: Adebrelimab, Trastuzumab Rezetecan Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer NCT07450976Phase 22 sites📍 Beijing📍 Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1904 for Injection PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients NCT05440227Phase 21 site📍 Taipei PhytoHealth Corporation · Tests: PG2 Lyo. Injection 500mg, Placebo 0.9% normal saline SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors NCT07022002Phase 21 site📍 Hangzhou Shenyang Sunshine Pharmaceutical Co., LTD. · Tests: SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy, SSGJ-705 combined with chemotherapy Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors NCT05533697Phase 1, Phase 239 sites📍 Los Angeles📍 San Francisco📍 Aurora ModernaTX, Inc. · Tests: mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. NCT06371274NA1 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: ATRA, Toripalimab YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer NCT07461454Phase 31 site📍 Shanghai MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL202, Eribulin, Capecitabine, Gemcitabine, Vinorelbine A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer NCT06184035Phase 1, Phase 22 sites📍 Adelaide📍 Melbourne Spago Nanomedical AB · Tests: [177Lu]Lu-SN201 Study of ACR-2316 in Specific Advanced Solid Tumors NCT06667141Phase 1, Phase 215 sites📍 Phoenix📍 Beverly Hills📍 Newport Beach Acrivon Therapeutics · Tests: ACR-2316 Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer NCT05098210Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer NCT06471205Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, PD-1 Monoclonal Antibody RGL-270 + ICI in Advanced NSCLC NCT07652125NA1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: RGL-270 in Combination with PD-1/PD-L1 Inhibitors, Physician's Choice SOC Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy NCT05903833Phase 215 sites📍 Augsburg📍 Bad Homburg📍 Dresden AGO Research GmbH · Tests: Pembrolizumab, Lenvatinib A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) NCT07554456Phase 2, Phase 31 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Tislelizumab, 5-Fluorouracil, Cisplatin, Paclitaxel 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma NCT06823427Phase 22 sites📍 Changsha📍 Nanjing Mabwell (Shanghai) Bioscience Co., Ltd. · Tests: 9MW2821, Toripalimab (JS001 ) Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer NCT06081959Phase 31 site📍 Beijing Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer NCT06993506n/a19 sites📍 Hefei📍 Beijing📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: SKB264 Monotherapy or Combination Therapy Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment NCT02029001Phase 27 sites📍 Bordeaux📍 Lyon📍 Lyon Centre Leon Berard · Tests: Nilotinib (400 mg BID), Everolimus (10 mg QD), Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD) Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer NCT04415853Phase 31 site📍 Beijing Sunshine Lake Pharma Co., Ltd. · Tests: Lerotinib, Irinotecan/Tegafur Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer NCT07073794Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Cancer Therapeutic Procedure, Cancer Therapeutic Procedure, Health Care Delivery, Questionnaire Administration Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study NCT05019703Phase 22 sites📍 Boston📍 Houston M.D. Anderson Cancer Center · Tests: Atezolizumab, Cabozantinib Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis NCT05059678NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: Best Practice, Educational Intervention, Questionnaire Administration A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B395, xT CDx with HLA-LOH assay Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598Phase 212 sites📍 Beverly Hills📍 La Jolla📍 Miami Replimune, Inc. · Tests: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) NCT07208149Phase 1, Phase 21 site📍 Beijing Shenzhen Majory Biotechnology Co., Ltd. · Tests: MR001 Bispecific Antibody for Injection
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy